Literature DB >> 22867774

Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.

Robert I Griffiths1, Michelle L Gleeson, Mark D Danese, Anthony O'Hagan.   

Abstract

OBJECTIVES: To assess the accuracy and precision of inverse probability weighted (IPW) least squares regression analysis for censored cost data.
METHODS: By using Surveillance, Epidemiology, and End Results-Medicare, we identified 1500 breast cancer patients who died and had complete cost information within the database. Patients were followed for up to 48 months (partitions) after diagnosis, and their actual total cost was calculated in each partition. We then simulated patterns of administrative and dropout censoring and also added censoring to patients receiving chemotherapy to simulate comparing a newer to older intervention. For each censoring simulation, we performed 1000 IPW regression analyses (bootstrap, sampling with replacement), calculated the average value of each coefficient in each partition, and summed the coefficients for each regression parameter to obtain the cumulative values from 1 to 48 months.
RESULTS: The cumulative, 48-month, average cost was $67,796 (95% confidence interval [CI] $58,454-$78,291) with no censoring, $66,313 (95% CI $54,975-$80,074) with administrative censoring, and $66,765 (95% CI $54,510-$81,843) with administrative plus dropout censoring. In multivariate analysis, chemotherapy was associated with increased cost of $25,325 (95% CI $17,549-$32,827) compared with $28,937 (95% CI $20,510-$37,088) with administrative censoring and $29,593 ($20,564-$39,399) with administrative plus dropout censoring. Adding censoring to the chemotherapy group resulted in less accurate IPW estimates. This was ameliorated, however, by applying IPW within treatment groups.
CONCLUSION: IPW is a consistent estimator of population mean costs if the weight is correctly specified. If the censoring distribution depends on some covariates, a model that accommodates this dependency must be correctly specified in IPW to obtain accurate estimates.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22867774     DOI: 10.1016/j.jval.2012.03.1388

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  8 in total

1.  Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

Authors:  Fadia T Shaya; Ian M Breunig; Brian Seal; C Daniel Mullins; Viktor V Chirikov; Nader Hanna
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

2.  Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients.

Authors:  Zhiyuan Zheng; Eberechukwu Onukwugha; Nader Hanna; Kaloyan Bikov; Brian Seal; C Daniel Mullins
Journal:  Adv Ther       Date:  2014-07-15       Impact factor: 3.845

3.  Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data.

Authors:  Mark D Danese; Carolina M Reyes; Michelle L Gleeson; Marc Halperin; Sandra L Skettino; Joseph Mikhael
Journal:  Med Care       Date:  2016-04       Impact factor: 2.983

4.  Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK.

Authors:  Mark D Danese; Michelle Gleeson; Lucie Kutikova; Robert I Griffiths; Ali Azough; Kamlesh Khunti; Sreenivasa Rao Kondapally Seshasai; Kausik K Ray
Journal:  BMJ Open       Date:  2016-08-05       Impact factor: 2.692

5.  The rate, cost and outcomes of parathyroidectomy in the united states dialysis population from 2016-2018.

Authors:  Mark D Danese; Kathleen M Fox; Jennifer L Duryea; Pooja Desai; Robert J Rubin
Journal:  BMC Nephrol       Date:  2022-06-21       Impact factor: 2.585

6.  Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.

Authors:  Bora Youn; Ira B Wilson; Vincent Mor; Nikolaos A Trikalinos; Issa J Dahabreh
Journal:  Health Serv Res       Date:  2021-03-07       Impact factor: 3.734

7.  Calculating Total Health Service Utilisation and Costs from Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment.

Authors:  Caroline Canavan; Joe West; Timothy Card
Journal:  Pharmacoeconomics       Date:  2016-02       Impact factor: 4.981

8.  Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data.

Authors:  Mark D Danese; Melinda Daumont; Esmond Nwokeji; Michelle Gleeson; John R Penrod; Deborah Lubeck
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.